NBI-1117568 Clinical Trials (2026): 6 Studies for Schizophrenia & Bipolar I Disorder

Where to Participate: All NBI-1117568 Trial Sites in the U.S. (101 sites across 16 states)

Every actively recruiting NBI-1117568trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

NBI-1117568 clinical trials at a glance: phase × recruitment status

Recruiting NBI-1117568 clinical trials (5)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NBI-1117568 clinical trials by indication

NBI-1117568 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All NBI-1117568 trials (6)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NBI-1117568 clinical trials: frequently asked questions

How many NBI-1117568 clinical trials are there?

6 NBI-1117568 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 1 is marked completed.

Are NBI-1117568 clinical trials recruiting in 2026?

Yes — 5 NBI-1117568 trials are actively recruiting in 2026, with 101 U.S. sites across 16 states. See the recruiting trials and the per-state site list further down this page.

What conditions is NBI-1117568 being studied for?

NBI-1117568 is being studied for Schizophrenia, Bipolar I Disorder, Mania. The trials are grouped by indication on this page.

What phase is NBI-1117568 in?

NBI-1117568 clinical trials span 4 Phase 3, 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors NBI-1117568 clinical trials?

The lead sponsor across the most NBI-1117568 trials is Neurocrine Biosciences. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming NBI-1117568as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.